Compare OOMA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | ARVN |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.6M | 516.2M |
| IPO Year | 2015 | 2018 |
| Metric | OOMA | ARVN |
|---|---|---|
| Price | $20.02 | $8.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 19 |
| Target Price | ★ $18.77 | $15.05 |
| AVG Volume (30 Days) | 314.1K | ★ 647.9K |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | 58.84 |
| EPS | ★ 0.09 | N/A |
| Revenue | $114,490,000.00 | ★ $262,600,000.00 |
| Revenue This Year | $20.35 | N/A |
| Revenue Next Year | $4.17 | N/A |
| P/E Ratio | $215.11 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $6.06 |
| 52 Week High | $21.96 | $14.22 |
| Indicator | OOMA | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 42.94 |
| Support Level | $10.78 | $7.90 |
| Resistance Level | $21.57 | $8.90 |
| Average True Range (ATR) | 0.88 | 0.31 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 52.24 | 6.00 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.